A Phase II, Randomized, Parallel Group, Placebo-controlled, Double-blinded, Dose-finding Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2018
At a glance
- Drugs ABY 035 (Primary)
- Indications Psoriasis
- Focus Proof of concept; Therapeutic Use
- Acronyms AFFIRM-35
- Sponsors Affibody
- 18 Jul 2018 Planned End Date changed from 7 Sep 2019 to 31 Jul 2019.
- 21 Mar 2018 According to a Affibody media release, the first patient has been dosed in this study.
- 17 Nov 2017 According to a Affibody Medical AB media release, the German regulatory agency BfArM approved the clinical trial application (CTA) for the Phase II study with ABY-035 in Nov 2017.